Respiratory Tract Infection Treatment Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
RESPIRATORY TRACT INFECTION TREATMENT MARKET
ANALYSIS

• Respiratory Tract Infection Treatment Market, by
  Drug Class (Antibiotics, Non-Steroidal
  Anti-Inflammatory Drug (NSAIDS), Cough
  Suppressant, Nasal Decongestant, and Others), by
  Disease Indication (Upper Respiratory Tract
  Infection and Lower Respiratory Tract Infection),
  by Distribution Channel (Hospital Pharmacies,
  Retail Pharmacies, and Online Pharmacies), and by
  Region (North America, Latin America, Europe,
  Asia Pacific, Middle East, and Africa) - Size,
  Share, trends, and Forecast to 2026
• The global respiratory tract infection treatment
  market was valued at US 35.64 Bn in 2017, and is
  expected to witness a CAGR of 6.5 over the
  forecast period (2018 2026).

3
Figure 1. Global Respiratory Tract Infection
Treatment Market Share Analysis (), By Product
Type
4
Market Drivers

• Increasing prevalence of respiratory diseases is
  expected to drive growth of the Respiratory Tract
  Infection Treatment Market
• Increasing prevalence of chronic respiratory
  diseases such as asthma, chronic pulmonary lung
  disease, pulmonary hypertension, and occupational
  lung disease are the major factors augmenting
  growth of the respiratory tract infection market.
• For instance, according to the Biomed Central
  Respiratory Research 2016, asthma and chronic
  obstructive pulmonary disease (COPD) are common
  chronic obstructive lung disorders characterized
  by variable airflow limitation and airway hyper
  responsiveness, affecting over 25 million people
  in the U.S.

5

• Various organizations, institutions, and agencies
  are working towards improving the diagnosis and
  medical care needed to reduce the global burden
  of respiratory diseases. For instance, the Global
  Alliance against Chronic Respiratory Diseases
  (GARD) was formed with the support from the World
  Health Organization (WHO) to control chronic
  respiratory diseases. The main objective of GARD
  is to develop simple and affordable strategies
  for chronic respiratory diseases (CRD) and to
  encourage economies to implement health promotion
  and CRD prevention policies.
• Presence of various drugs in pipeline, which is
  expected to be launched over the forecast period
  will also boost the market growth of respiratory
  tract infection treatment. Some of the drugs in
  the pipeline include Relenza (GSK), MK7264 (Merck
  Co.), Presatovir (Gilead), AZD7594, and PT010
  (AstraZeneca).

6
Market Restraints

• However, presence of various generic
  manufacturers and low cost of various drugs
  including antibiotics in the market may hinder
  the respiratory tract infection treatment market
  to some extent during the forecast period.

7
Respiratory Tract Infection Treatment Market-
Regional Analysis

• On the basis of region, the global respiratory
  tract infection treatment market is segmented
  into North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa.
• North America is expected to hold a dominant
  position in the global respiratory tract
  infection treatment market over the forecast
  period, owing to increasing number of
  hospitalizations and emergency visits associated
  with acute or life threatening medical problems.
• According to the study by Society of Critical
  Care Medicine 2016, over 5.7 million patients are
  admitted annually in intensive care units (ICUs)
  in the U.S. for support of airway, breathing or
  circulation, and comprehensive management of
  injury.

8

• Also, according to the Centers for Disease
  Control and Prevention (CDC), 2017, around 1.7
  million emergency department visits with chronic
  and unspecified bronchitis were registered in the
  U.S. hospital facilities.
• Furthermore, several pharmaceutical and
  biotechnological companies are focusing on
  expanding their business in Asia Pacific region,
  to maximize their RD activities, as this region
  provides better access to patients for clinical
  trials, with low cost operational efficiencies.
  Increasing government investments in research and
  development, patient awareness, improved health
  care infrastructure and facilities, high
  disposable income, and prevalence of unhealthy
  lifestyle are also expected to foster growth of
  the respiratory tract infection treatment market
  in the Asia Pacific region.

9
Figure 2 Global Respiratory Tract Infection
Treatment Market Share (), By Region
10
Key Development

• Increasing approval of new drugs by the Food and
  Drug Administration (FDA) is also expected to
  propel the overall market growth over the
  forecast period. For instance, in November 2017,
  the U.S. FDA approved Fasenra (Benralizumab)
  manufactured by AstraZeneca, a respiratory
  biologic for patients aged 12 years and older who
  are suffering from asthma, and with an
  eosinophilic phenotype.

11
Key Players

• Key players operating in the global respiratory
  tract infection treatment market include Abbott
  Laboratories, AstraZeneca, Plc, Abbvie Inc.,
  Boehringer Ingelheim GmbH, Cipla Pharmaceutical
  Company, GlaxoSmithKline plc, Pfizer Inc., Merck
  Co., Novartis AG, F. Hoffman La Roche Ltd,
  Sanofi, and Teva Pharmaceutical Industries Ltd.

12

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/respiratory-tract-infection-treatm
  ent-market-2030

13
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

14
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

15

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/